March 7, 2019 | Michael Easterling
Australian lobster fisherman David Thompson traveled 9,000 miles for treatment at City of Hope after being diagnosed with Stage 4 oropharyngeal cancer. Given just six weeks to live, he is thriving more than a year after participating in an immunotherapy clinical trial.
TGen IDs gene associated with most common liver cancer
April 19, 2019 | City of Hope
AKR1B10 could help provide early detection of hepatocellular carcinoma, and play a role in monitoring and treating this growing cause of cancer death.
Combined immunotherapy could tackle advanced cancers
April 15, 2019 | Zen Vuong
City of Hope physician-scientists recently opened two clinical trials to investigate a combination of cytokines and immunotherapy that may be able to transform nearly impossible-to-treat cancer into a disease that can be corralled into remission.
People miss key area of face with sunscreen products, study finds
April 11, 2019 | Samantha Bonar
People commonly miss their eyelids when applying sunscreen or moisturizers containing SPF. This is of concern because this fragile area is prone to skin cancer.
City of Hope awarded $7.5M to develop treatment for rare cancer
April 3, 2019 | Zen Vuong
City of Hope recently received $7.5 million in grant awards to study a rare type of blood cancer that affects the skin: cutaneous T cell lymphoma.
City of Hope study finds diabetes A1c test misses most cases
March 28, 2019 | City of Hope
The hemoglobin A1c blood test is widely used to diagnose type 1 and type 2 diabetes but it is actually unable to detect the disease in most patients, according to a new study presented March 23 at the Endocrine Society’s annual meeting.
Researchers detail new findings at 2019 AACR meeting
March 28, 2019 | Zen Vuong
City of Hope will showcase ongoing studies and data on chimeric antigen receptor (CAR) T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research annual meeting from March 29 through April 3 in Atlanta.
Diagnosis and treatment at the same time? With theranostics, it's possible
March 27, 2019 | Zen Vuong
A City of Hope scientist and his colleagues have developed a user-friendly approach to creating “theranostics” — therapy combined with diagnostics — that target specific tumors and diseases.
Patient diversity not reflected by cell lines used for research, study shows
March 13, 2019 | Zen Vuong
City of Hope scientist, Rick Kittles, Ph.D., and his colleagues found that some commercial cell lines used for countless laboratory studies have mislabeled ancestry when it comes to minorities.
‘Watch-and-wait’ approach for low-risk prostate cancer not without dangers
March 7, 2019 | Malcolm Bedell
Men diagnosed with “low-risk” prostate cancer are increasingly refusing more aggressive treatment in favor of a watch-and-wait approach. However, determining which patients truly fall into the “low-risk” category can prove more complicated than some tests would make it seem.